Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Exchange Rate Effect: 2019-2025

Historic Exchange Rate Effect for Legend Biotech (LEGN) over the last 7 years, with Sep 2025 value amounting to $2.8 million.

  • Legend Biotech's Exchange Rate Effect rose 441.41% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 289.48%. This contributed to the annual value of -$2.1 million for FY2024, which is 405.72% down from last year.
  • Per Legend Biotech's latest filing, its Exchange Rate Effect stood at $2.8 million for Q3 2025, which was down 36.12% from $4.4 million recorded in Q2 2025.
  • Over the past 5 years, Legend Biotech's Exchange Rate Effect peaked at $4.4 million during Q2 2025, and registered a low of -$2.4 million during Q1 2023.
  • For the 3-year period, Legend Biotech's Exchange Rate Effect averaged around $661,364, with its median value being $524,000 (2024).
  • In the last 5 years, Legend Biotech's Exchange Rate Effect plummeted by 23,640.00% in 2023 and then soared by 49,244.44% in 2025.
  • Quarterly analysis of 5 years shows Legend Biotech's Exchange Rate Effect stood at $78,000 in 2021, then crashed by 1,521.79% to -$1.1 million in 2022, then surged by 231.11% to $1.5 million in 2023, then tumbled by 256.46% to -$2.3 million in 2024, then soared by 441.41% to $2.8 million in 2025.
  • Its Exchange Rate Effect was $2.8 million in Q3 2025, compared to $4.4 million in Q2 2025 and $1.4 million in Q1 2025.